Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.44 |
| ▸ | NOS2 | P35228 | 4/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 9/20 | 0.36 |
| ▸ | BCHE | P06276 | 5/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24283716 | 0.98 | NOS3 (0.42) | NOS3NOS2NOS1NPC1RAB9A | |
| SCHEMBL25771760 | 0.98 | NOS3 (0.42) | NOS3NOS2NOS1NPC1RAB9A | |
| SCHEMBL19005861 | 0.98 | NOS3 (0.42) | NOS3NOS2NOS1NPC1RAB9A | |
| SCHEMBL795850 | 0.95 | GRM4 (0.40) | NOS3NOS2NOS1NPC1RAB9A | |
| SCHEMBL27549216 | 0.94 | NOS3 (0.40) | NOS3NOS2NOS1NPC1RAB9A | |
| SCHEMBL28217559 | 0.79 | GRM4 (0.47) | NOS3NOS2NOS1NPC1RAB9A | |
| SCHEMBL30666539 | 0.76 | NOS3 (0.39) | NOS3NOS2NOS1KDM4EGRM4 | |
| SCHEMBL8264767 | 0.76 | NOS3 (0.39) | NOS3NOS2NOS1GRM4ACHE | |
| SCHEMBL22270533 | 0.76 | NOS3 (0.39) | NOS3NOS2NOS1NPC1RAB9A | |
| SCHEMBL2087344 | 0.76 | NOS3 (0.39) | NOS3NOS2NOS1KDM4EGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4727149-A | Preparation of nitriles of fused ring pyridine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1988-02-23 | — | — | US | claimed |
| US-4707552-A | Preparation of nitriles and thioamides of fused ring pyridine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1987-11-17 | — | — | US | claimed |
| CN-115721671-A | Method for extracting and separating effective components of liquorice root in full-industrial-chain cooperation manner | 李玉山 | 2023-03-03 | — | — | CN | disclosed |
| US-11583524-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-21 | — | — | US | disclosed |
| EP-3782991-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | The Scripps Research Institute (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3686196-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| US-20200121667-A1 | Inhibitors Of The Interaction Between MDM2 And P53 | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-23 | — | — | US | disclosed |
| US-20190144396-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| US-10189843-B2 | Fused pyrazole derivative having autotaxin inhibitory activity | THE UNIVERSITY OF TOKYO (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-05 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| US-4727149-A | Preparation of nitriles of fused ring pyridine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1988-02-23 | — | — | US | disclosed |
| US-4707552-A | Preparation of nitriles and thioamides of fused ring pyridine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1987-11-17 | — | — | US | disclosed |
| US-4577022-A | Silyl compounds | JOHN WYETH & BROTHER, LTD. (GB) | 1986-03-18 | — | — | US | disclosed |
| US-4547510-A | ANTIULCER AGENTS | JOHN WYETH & BROTHER LTD. (GB) | 1985-10-15 | — | — | US | disclosed |
| US-4529798-A | Reacting the correcponding lithium, sodium, potassium or magnesium halide compound with a aminonitrile compound | JOHN WYETH & BROTHER LIMITED (GB) | 1985-07-16 | — | — | US | disclosed |
| EP-0054384-B1 | PROCESS FOR PREPARING PYRIDINE DERIVATIVES | JOHN WYETH & BROTHER LIMITED (GB) | 1984-06-27 | — | — | EP | disclosed |
| EP-0054384-A1 | Process for preparing pyridine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1982-06-23 | — | — | EP | disclosed |
| US-4160094-A | Tetrahydroquinoline derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1979-07-03 | — | — | US | disclosed |
| US-3991065-A | ANTIULCER AGENTS, CHEMICAL INTERMEDIATES | JOHN WYETH & BROTHER LIMITED (EN) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189843-B2 | Fused pyrazole derivative having autotaxin inhibitory activity | ENPP2, PRTN3, TPX2 | NOS3 3248/4885NOS2 4314/4885NOS1 3553/4885 |
| US-11583524-B2 | Inhibitors of the interaction between MDM2 and P53 | TP53, MDM2, TP53BP1 | NOS3 2278/4885NOS2 2697/4885NOS1 2022/4885 |
| US-20200121667-A1 | Inhibitors Of The Interaction Between MDM2 And P53 | TP53, MDM2, TP53BP1 | NOS3 2511/4885NOS2 2862/4885NOS1 2148/4885 |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | NOS3 4447/4885NOS2 4606/4885NOS1 4603/4885 |
| US-20190144396-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | NOS3 1863/4885NOS2 975/4885NOS1 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.